一、基本信息
李文骥，男，1978年4月出生，博士,扬州大学医学院****，医学院中马分子肿瘤及中药递送国际联合研究中心主任, 博士生导师，主持并参与11项国内外课题包括5项美国NIH R01项目和国自然面上项目，共发表SCI论文30篇。SCI三区期刊Journal of Biochemical and Molecular Toxicology 编委，10多家SCI期刊特约审稿人，澳洲西悉尼大学研究生海外评审专家。指导硕士生获得2018年江苏省研究生实践创新计划校立院助1项。指导的本科生团队获2020年江苏省大学生创业训练计划省级立项2项，2020年“互联网+”大赛扬州大学医学院二等奖、三等奖各一项。邮箱：wenji_li@yzu.edu.cn/wyttr@hotmail.com
二、教育经历
2014年4月—2018年6月，美国新泽西罗格斯大学药学院博士后
2006年8月—2011年10月, 新加坡国立大学药学系博士
2003年12月—2007年6月，新加坡国立大学药理系硕士
2001年9月—2004年7月，上海中医药大学中医内科硕士
1996年9月—2001年6月，南京中医药大学针灸学士
三、研究方向
主要从事肿瘤在表观遗传(组) 学的变化及天然产物的干预研究
四、承担项目
1.国家自然科学基金面上项目“姜黄素通过表观遗传调控Nrf2/ARE和TGF-β/Smad预防炎症相关前列腺癌的研究”。项目号**，2020/01-2023/12，54万，主持
2.扬州大学高层次人才启动项目“中药防治肿瘤相关疾病研究”, 2018/07—2022/07, 40万，主持
五、代表性论著
1.Wenji Li^#*, Kai Sun^#, Fang Hu, Longfei Chen, Xing Zhang, Fuxing Wang, Bingchun Yan, Protective effects of natural compounds against oxidative stress in ischemic diseases and cancers via activating the Nrf2 signaling pathway: A mini review (Journal of biochemical and molecular toxicology. 2020 Oct 28;e22658.doi: 10.1002/jbt.22658. Online ahead of print.)
2.Wenji Li^#, Davit Sargsyan^#, Renyi Wu, Shanyi Li, Lujing Wang, David Cheng and Ah-Ng Kong*，DNA Methylome and Transcriptome Alterations in High Glucose-Induced Diabetic Nephropathy Cellular Model and Identification of Novel Targets for Treatment by Tanshinone IIA　(Chemical Research in Toxicology. 2019 Oct 21;32(10):1977-1988. doi: 10.1021/acs.chemrestox.9b00117. Epub 2019 Sep 17.)
3.Wenji Li^#, Hilly Yang^#, Brian Buckley, Lujing wang and Ah-Ng Kong. A Novel Triple Stage Ion Trap MS method validated for curcumin pharmacokinetics application: a comparison summary of the latest validated curcumin LC/MS methods.(Journal of Pharmaceutical and Biomedical Analysis Volume 156, 2018 July 15;156:116-124. doi: 10.1016/j.jpba.2018.04.022. Epub 2018 Apr 17. PMID: ** DOI: 10.1016/j.jpba.2018.04.022)
4. Wenji Li^#, Ying Huang^#, Davit Sargsyan, Tin Oo Khor, Yue Guo, Limin Shu, Anne Yuqing Yang, Chengyue Zhang, Ximena Paredes-Gonzalez, Michael Verzi, Ronald P Hart, and Ah-Ng Kong. Epigenetic alterations in TRAMP mice: genomic DNA methylation profiling using MeDIP-seq. (Cell & Bioscience2018 Jan 12;8:3. doi: 10.1186/s13578-018-0201-y. eCollection 2018.)
5. Wenji Li, Zheng-Yuan Su, Yue Guo, Chengyue Zhang, Renyi Wu, Linbo Gao, Xi Zheng, Zhi-Yun Du, Kun Zhang, and Ah-Ng Tony Kong. Curcumin Derivative Epigenetically Reactivates Nrf2 Antioxidative Stress Signaling in Mouse Prostate Cancer TRAMP C1 Cells. (Chemical Research in Toxicology 2018 Feb 19; 31(2):88-96. doi: 10.1021/acs.chemrestox.7b00248. Epub 2018 Jan 8.)
6. Wenji Li,Yue Guo, Chengyue Zhang, Renyi Wu, Anne Yuqing Yang, John Gaspar, and Ah-Ng Tony Kong. Dietary phytochemicals and cancer chemoprevention: A perspective on oxidative stress, inflammation and epigenetics. (Chemical Research in Toxicology. 2016 Dec 19; 29(12):2071-2095. DOI: 10.1021/acs.chemrestox.6b00413)
7.Wenji Li^#, Doug Pung^#, Zheng-Yuan Su, Yue Guo, Chengyue Zhang, Anne Yuqing Yang, Xi Zheng, Zhi-Yun Du, Kun Zhang, and Ah-Ng Kong. Epigenetics Reactivation of Nrf2 in Prostate TRAMP C1 Cells by Curcumin Analogue FN1. (Chemical Research in Toxicology. 2016 Apr 18;29(4):694-703. doi: 10.1021/acs.chemrestox.6b00016. Epub 2016 Mar 29)
8. Wenji Li*, Jia Yang, XiaoshuZhu, Shu-chuen Li and Paul C. Ho. Correlation between tea consumption and prevalence of hypertension among Singaporean Chinese residents aged ?40 years. (Journal of Human Hypertension. 2016 Jan;30(1):11-7. DOI: 10.1038/jhh.2015.45. Epub 2015 May 28. *, corresponding author)
9.Wenji Li, Ka-yun Ng, Paul W S Heng. Development and Evaluation Of Optimized Sucrose Ester Stabilized Nanosuspensions Of Oleanolic Acid Via Wet Ball Milling By Design Of Experiments (DOE). (Biological &Pharmaceutical bulletin, 2014;37(6):926-37.)
10.Wenji Li, Surajit Das, Ka-yun Ng, Paul WS Heng. Formulation, Biological And Pharmacokinetic Study Of A Sucrose Ester Stabilized Nnanosuspensions Of Oleanolic Acid. (Pharmaceutical Research2011 Aug;28(8):2020-33. doi: 10.1007/s11095-011-0428-3. Epub 2011 Apr 9.)
11. 东南亚草药组合提取物的制备及应用Preparation & Application of Southeastern Asian herbs extraction combination (专利号ZL4.1, 2019.11.08授权)
六、获奖情况
1. 2018年6月 江苏省引凤工程第三届创新创业大赛三等奖
2. 2019年9月第六届中国（泰州）国际医药高层次人才创新创业大赛优胜奖
3. 2019年11月 重庆国际生物城生物医药双创英才项目”最具市场前景奖”